Safety Profile
Known Safety Concerns
- Manganism -- Parkinson-like neurotoxicity with excess
- Brain preferentially accumulates manganese
- UL: 11 mg/day -- check all supplement sources
- Neurodevelopmental risk in children with excess intake
Contraindications
- Manganism -- Parkinson-like neurotoxicity with excess
- Brain preferentially accumulates manganese
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Manganese sulfate is an inorganic manganese salt used in supplements. Like all manganese forms, chronic excess causes manganism — a Parkinson-like neurological disorder. The brain accumulates manganese preferentially. The UL is 11 mg per day. Manganese sulfate has lower bioavailability than chelated forms but the toxicity risk is the same.
Biological and Chemical Classification
- Scientific Name
- Manganese sulfate (MnSO4)
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Mineral
- Evidence consistency: High consistency across studies (100%)
- Manganism -- Parkinson-like neurotoxicity with excess
- Brain preferentially accumulates manganese
- UL: 11 mg/day -- check all supplement sources
- Neurodevelopmental risk in children with excess intake
The available scientific evidence for Manganese Sulfate indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 24 მარ 2026, 16:45
Evidence Distribution
-
Observational / other LOW evidence YELLOWEarly Diagnosis and Targeted Therapy in SLC39A8-Congenital Disorder of Glycosylation: A Case Report From Bulgaria. ↗Varbanova V et al.. Early Diagnosis and Targeted Therapy in SLC39A8-Congenital Disorder of Glycosylation: A Case Report From Bulgaria.. Cureus. 2026. PMID:41669571.PMID 41669571 ↗Journal CureusYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41669571/
-
Observational / other LOW evidence YELLOWCatalytic performance of u03b1-MnO(2) nanorods on the degradation of rhodamine B using chlorine dioxide as an oxidant. ↗Ri MS et al.. Catalytic performance of u03b1-MnO(2) nanorods on the degradation of rhodamine B using chlorine dioxide as an oxidant.. RSC Adv. 2025. PMID:41333655.PMID 41333655 ↗Journal RSC AdvYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41333655/
-
Observational / other LOW evidence YELLOWDevelopment and characterization of manganese-doped hydroxyapatite-incorporated wet-electrospun polycaprolactone scaffolds. ↗Samiei A et al.. Development and characterization of manganese-doped hydroxyapatite-incorporated wet-electrospun polycaprolactone scaffolds.. Biomed Mater. 2025. PMID:41192054.PMID 41192054 ↗Journal Biomed MaterYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41192054/
-
Observational / other LOW evidence YELLOWFormulations of novel microbial medium from beetroot powder: a sustainable substitute for commercial Man-de-Rogosa Sharp agar (MRS) in cultivating lactic acid bacteria. ↗Oussama B et al.. Formulations of novel microbial medium from beetroot powder: a sustainable substitute for commercial Man-de-Rogosa Sharp agar (MRS) in cultivating lactic acid bacteria.. World J Microbiol Biotechnol. 2025. PMID:41075044.PMID 41075044 ↗Journal World J Microbiol BiotechnolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41075044/
-
Observational / other LOW evidence YELLOWOptimization of culture medium for probiotic bacterium Lacticaseibacillus casei UT1 to enhance biomass production using the Taguchi statistical method. ↗Afshar S et al.. Optimization of culture medium for probiotic bacterium Lacticaseibacillus casei UT1 to enhance biomass production using the Taguchi statistical method.. J Microbiol Methods. 2025. PMID:41005482.PMID 41005482 ↗Journal J Microbiol MethodsYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41005482/
-
Observational / other LOW evidence YELLOWEfficient separation of impurities from pyrolusite and the enhancement of its products for improving the performance of lithium-ion batteries. ↗Zang R et al.. Efficient separation of impurities from pyrolusite and the enhancement of its products for improving the performance of lithium-ion batteries.. Chemosphere. 2025. PMID:40896883.PMID 40896883 ↗Journal ChemosphereYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40896883/
-
Observational / other LOW evidence YELLOWPhysiological, transcriptomic, and metabolomic integrated analyses reveal key factors involved in manganese sulfate mitigating cadmium toxicity in wheat. ↗Wang Y et al.. Physiological, transcriptomic, and metabolomic integrated analyses reveal key factors involved in manganese sulfate mitigating cadmium toxicity in wheat.. Plant Physiol Biochem. 2025. PMID:40752100.PMID 40752100 ↗Journal Plant Physiol BiochemYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40752100/
-
Observational / other LOW evidence YELLOWOptimizing nutrient management protocol for Ophiopogon japonicus-corn intercropping: impacts on growth, yield, and medicinal quality. ↗Cai X et al.. Optimizing nutrient management protocol for Ophiopogon japonicus-corn intercropping: impacts on growth, yield, and medicinal quality.. PeerJ. 2025. PMID:40677750.PMID 40677750 ↗Journal PeerJYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40677750/
-
Observational / other LOW evidence YELLOWThe Effects of Polymer-Nitrogen Fertilizer on Biomes in Drip-Irrigated Wheat Soil. ↗Sun Y et al.. The Effects of Polymer-Nitrogen Fertilizer on Biomes in Drip-Irrigated Wheat Soil.. Microorganisms. 2025. PMID:40572222.PMID 40572222 ↗Journal MicroorganismsYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40572222/
-
Observational / other LOW evidence YELLOW[Effects of potassium and trace elements on soil ecological functions and health status in Loess Plateau dryland farmland]. ↗Guo H et al.. [Effects of potassium and trace elements on soil ecological functions and health status in Loess Plateau dryland farmland].. Ying Yong Sheng Tai Xue Bao. 2025. PMID:40371499.PMID 40371499 ↗Journal Ying Yong Sheng Tai Xue BaoYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40371499/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Manganese Sulfate. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Moderate classification for Manganese Sulfate
A score of 4.0 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.